论文部分内容阅读
目的观察沙立度胺(反应停)辅助治疗非霍奇金淋巴瘤(NHL)的临床效果,并测定治疗前后淋巴瘤组织微血管密度(MVD)及血管内皮细胞生长因子(VEGF)、核因子-κB(NF-κB)活性的变化。方法采用免疫组化方法测定实验组17例及对照组14例NHL患者淋巴瘤组织中的VEGF、NF-κB、MVD表达。结果两组病例的有效率[完全缓解(CR)+部分缓解(PR)]分别为70.6%和64.3%,差异无统计学意义(P>0.05)。但CR患者随访6个月以后,实验组1例复发,对照组3例复发;治疗后MVD、VEGF与对照组相比差异有统计学意义,MVD(42.3±19.2)%vs(57.8±19.8)%,VEGF(21.3±5.4)%vs(31.7±5.8)%(P<0.05,P<0.01),NF-κB与对照组相比差异无统计学意义(P>0.05)。结论反应停联合化疗可以维持NHL患者的持续缓解状态,减少复发;其通过降低NHL患者淋巴瘤组织中VEGF的表达,从而减少其MVD而抑制血管新生来达到此作用的。
Objective To observe the clinical effect of thalidomide adjuvant in the treatment of non - Hodgkin ’s lymphoma (NHL) and to determine the changes of the microvessel density (MVD), vascular endothelial growth factor (VEGF), nuclear factor - κB (NF-κB) activity changes. Methods The expression of VEGF, NF-κB and MVD in 17 cases of NHL from experimental group and 14 cases of control group were detected by immunohistochemistry. Results The effective rate [complete remission (CR) + partial remission (PR)] was 70.6% and 64.3% in both groups, with no significant difference (P> 0.05). However, after 6 months of follow-up in CR patients, 1 case recurred in the experimental group and 3 cases recurred in the control group. The difference of MVD and VEGF between the two groups was statistically significant (MVD 42.3 ± 19.2% vs 57.8 ± 19.8% %, VEGF (21.3 ± 5.4)% vs (31.7 ± 5.8)% (P <0.05, P <0.01). There was no significant difference between NF-κB and control group (P> 0.05). Conclusions Chemotherapy combined with Chemotherapy can maintain sustained remission status and reduce recurrence in NHL patients. It can achieve this effect by reducing the expression of VEGF in lymphoma tissue of NHL patients, and reducing the MVD and angiogenesis.